Participants will be given the company's 20-valent pneumococcal conjugate vaccine (20vPnC) candidate - which helps fight illness caused by pneumococcal bacteria -along with a third dose of the Pfizer-BioNTech COVID-19 shot. The aim of the study is to understand if the combination of the vaccines is safe, and the immune response after adding the pneumonia vaccine to the existing COVID-19 vaccine, the company said. Some experts also believe a pneumococcal vaccine can help combat COVID-19. Pfizer is running tests of their vaccine booster shot combined with a pneumococcal conjugate vaccine. Bourla said his company is still in the early stages of trials for a booster shot, but some data on the shots may be available soon.

Source: The Nation May 24, 2021 18:00 UTC